A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

摘要: Purpose Panitumumab, a fully human antibody targeting the epidermal growth factor receptor, is active in patients with metastatic colorectal cancer (mCRC). This trial evaluated panitumumab added to bevacizumab and chemotherapy (oxaliplatin- irinotecan-based) as first-line treatment for mCRC. Patients Methods were randomly assigned within each cohort or without 6 mg/kg every 2 weeks. The primary end point was progression-free survival (PFS) oxaliplatin cohort. Tumor assessments performed 12 weeks reviewed centrally. Results A total of 823 230 irinotecan cohorts, respectively. Panitumumab discontinued after planned interim analysis 812 showed worse efficacy arm. In final analysis, median PFS 10.0 11.4 months control arms, respectively (HR, 1.27; 95% CI, 1.06 1...